Physician profile
Bruce Feldman
NPI 1528095684
$1,713.22
in general payments reported to CMS, 2019-2025
13 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $139 · 2021: $473 · 2022: $353 · 2023: $24.89 · 2024: $172 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $366.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.47 | 2021-2023 | Jardiance |
| Boston Scientific Corporation | $228.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $201.89 | 2019-2021 | |
| Shockwave Medical, INC | $170.06 | 2025 | |
| Janssen Pharmaceuticals, INC | $163.32 | 2021-2022 | |
| Heartflow, INC. | $126.96 | 2024 | |
| Esperion Therapeutics, INC. | $125.00 | 2021 | |
| Abbott Laboratories | $124.80 | 2022 | |
| Lundbeck LLC | $124.80 | 2019 | |
| Lilly USA, LLC | $96.00 | 2019 | |
| Abiomed | $44.95 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.46 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.